Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review

Abstract

is missing (Short communication)

Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up

“…To our knowledge, there has been no prior report of successful treatment of comorbid AD and AA by switching to abrocitinib after dupilumab failure (Table 2). 18,[31][32][33][34][35] Throughout our 1-year follow-up, we observed a favorable response to abrocitinib with no adverse reactions, suggesting its safety in treating such conditions in children.…”

“…18 Based on this review, we have summarized the latest reports of JAK inhibitor treatment for pediatric AA in the past 2 years (Table 1). 18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. 18,[31][32][33][34][35] Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years.…”

“…18,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35] Six cases involved the use of upadacitinib (selective JAK1 inhibitor) and abrocitinib (selective JAK1 inhibitor) in treating pediatric patients with AA, showing good tolerability. 18,[31][32][33][34][35] Upadacitinib and abrocitinib have been approved for severe AD in children aged ≥12 years. 36 Selective JAK1 inhibitors have potential safety advantages because of their specific pathway targeting, offering greater JAK2-related hematopoietic function preservation than non-selective inhibitors.…”

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

“…The study by Yu and Ren reported a case of successful treatment with UPA in a child with alopecia universalis (AU) and mild AD (EASI 2.5). 112 The patient experienced substantial hair regrowth after 4 weeks of UPA treatment, with a marked improvement in the SALT score from 100% at baseline to 0% at week 12. Similarly, Bourkas and Sibbald reported a pediatric patient with AA and severe AD achieving a reduction in the SALT score from 95.1±9.6 at baseline to 77.6±28.2 at week 4, 113 indicating a positive response to UPA therapy.…”

“…More data regarding the pediatric populations are coming from case series. The study by Dianhe Yu and Yunqing Ren reported a case of successful treatment with UPA in a child with alopecia universalis (AU) and mild AD (EASI 2.5) (112). The patient experienced substantial hair regrowth after 4 weeks of UPA treatment, with a marked improvement in the SALT score from 100% at baseline to 0% at week 12.…”